Weekly roundup: From BIO 2025 to building boards

/in

Rewind Therapeutics strengthens scientific advisory board with leading international neurology experts as it advances its first-in-class remyelination therapy  Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, has appointed four internationally recognised innovators in neurology –  Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan – to its Scientific Advisory Board (SAB). The […]

Read more

Hot topic: Should we keep renaming diseases?

/in

Thursday June 12 was Global Fatty Liver Day. But until 2018 it was known as International NASH Day – NASH being short for ‘non-alcoholic steatohepatitis’. The name of the awareness day was changed to increase awareness of all types of fatty liver disease, as NASH is just one type – a more serious type – […]

Read more

Weekly roundup: Innovation and deals for Optimum’s clients

/in

SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]

Read more

Hot topic: Science in the time of TikTok

/in

Who can fail to have been impressed by the amazing developments in the field of oncology on display at ASCO 2025, everything from immunotherapies to ADCs to new biomarkers.  But Optimum was struck by a number of studies which illustrate a challenge that isn’t clinical or technical, but vital, nonetheless.  They were about trust.  Over […]

Read more

Weekly roundup: June kickstarts with an abundance of appointments

/in

iOnctura bolsters leadership team with new appointments iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, announces the appointments of Steven Sciuto as Chief Financial Officer and Michelle Tsai PharmD as Chief Operating Officer. Amber Implants announces successful one-year follow-up data in first-in-human clinical of VCFix® Spinal System Amber Implants announced  completion of the […]

Read more